About: Ublituximab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

Ublituximab is an immunomodulator. It binds to CD20. It is in phase III clinical trials for multiple sclerosis. It is also in "U2" phase III clinical trials for chronic lymphocytic leukemia in combination with Umbralisib.

Property	Value
dbo:abstract	Ublituximab is an immunomodulator. It binds to CD20. It is in phase III clinical trials for multiple sclerosis. It is also in "U2" phase III clinical trials for chronic lymphocytic leukemia in combination with Umbralisib. (en)
dbo:casNumber	1174014-05-1
dbo:fdaUniiCode	U59UGK3IPC
dbo:kegg	D11243
dbo:wikiPageID	33051889 (xsd:integer)
dbo:wikiPageLength	3472 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1117140811 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Umbralisib dbr:Chronic_lymphocytic_leukemia dbr:Multiple_sclerosis dbc:Monoclonal_antibodies dbr:CD20 dbr:Immunotherapy dbr:Phases_of_clinical_research
dbp:atcPrefix	None (en)
dbp:casNumber	1174014 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:kegg	D11243 (en)
dbp:mabType	mab (en)
dbp:source	xi/o (en)
dbp:target	dbr:CD20
dbp:type	mab (en)
dbp:unii	U59UGK3IPC (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	470619391 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Immunosuppressants dbt:Monoclonal-antibody-stub dbt:Monoclonals_for_tumors
dcterms:subject	dbc:Monoclonal_antibodies
gold:hypernym	dbr:Immunomodulator
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459
rdfs:comment	Ublituximab is an immunomodulator. It binds to CD20. It is in phase III clinical trials for multiple sclerosis. It is also in "U2" phase III clinical trials for chronic lymphocytic leukemia in combination with Umbralisib. (en)
rdfs:label	Ublituximab (en)
owl:sameAs	freebase:Ublituximab yago-res:Ublituximab wikidata:Ublituximab https://global.dbpedia.org/id/4wZdR dbr:Ublituximab
prov:wasDerivedFrom	wikipedia-en:Ublituximab?oldid=1117140811&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Ublituximab
is dbo:wikiPageWikiLink of	dbr:Umbralisib dbr:Richter's_transformation dbr:CD20 dbr:List_of_therapeutic_monoclonal_antibodies dbr:Multiple_sclerosis_drug_pipeline dbr:List_of_drugs:_U
is foaf:primaryTopic of	wikipedia-en:Ublituximab